Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Treating mantle cell lymphoma (Part 2)

Andre Goy and John Gribben • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma

Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Andre Goy (John Theurer Cancer Center, Hackensack, NJ) at the 2014 American Society of Hematology (ASH) Annual Meeting about novel therapies for mantle cell lymphoma (MCL). Topics include novel biologic therapies, such as lenalidomide-based and ibrutinib-based therapies; molecularly distinct MCL subtypes; and treatment of different age groups.

More from Andre Goy

3:54
The latest developments in CAR-T and BiTE therapies for B-cell and mantle cell lymphoma
Andre Goy • 5 Jun 2022
2:02
Highlights in the field of lymphoma from ASCO 2022
Andre Goy • 5 Jun 2022
3:36
ASH 2014: Treating mantle cell lymphoma (Part 1)
Andre Goy et al. • 5 Dec 2014
2:21
ASH 2014: Treating mantle cell lymphoma (Part 3)
Andre Goy et al. • 5 Dec 2014

More from John Gribben

2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

Related Videos

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
0:44
A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
Stefania Bramanti • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals